SG11201809879WA - Novel antibodies specifically binding to zika virus epitopes and uses thereof - Google Patents
Novel antibodies specifically binding to zika virus epitopes and uses thereofInfo
- Publication number
- SG11201809879WA SG11201809879WA SG11201809879WA SG11201809879WA SG11201809879WA SG 11201809879W A SG11201809879W A SG 11201809879WA SG 11201809879W A SG11201809879W A SG 11201809879WA SG 11201809879W A SG11201809879W A SG 11201809879WA SG 11201809879W A SG11201809879W A SG 11201809879WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibodies
- pct
- rule
- relates
- Prior art date
Links
- 241000907316 Zika virus Species 0.000 title abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000001455 Zika Virus Infection Diseases 0.000 abstract 1
- 208000020329 Zika virus infectious disease Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 1111111111111111111111111H11111H11111111111111011111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/011283 Al 18 January 2018 (18.01.2018) W I P0 I P C T (51) International Patent Classification: C07K 16/10 (2006.01) A61K 39/395 (2006.01) A61P 31/12 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2017/067581 (22) International Filing Date: 12 July 2017 (12.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2016/066684 13 July 2016 (13.07.2016) EP (71) Applicant: HUMABS BIOMED SA [CH/CH]; Via Mira- sole 1, 6500 Bellinzona (CH). (72) Inventor: CORTI, Davide; Via Mirasole 1, 6500 Bellinzona (CH). (74) Agent: VON STOSCH, Andreas et al.; Prinzregentenstr. 22, 80538 Munich (DE). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) under Rule 4.17: Declarations of inventorship (Rule 4.17(iv)) — 1- 2 0 , 1 Published: with international search report (Art. 21(3)) en cc — ei with sequence listing part of description (Rule 5.2(a)) 1-1 ,-1 (54) Title: NOVEL ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF ---- (57) : The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. GC , 1 The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids C::::) that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use N of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment 0 of ZIKV infection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/066684 WO2018010789A1 (en) | 2016-07-13 | 2016-07-13 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| PCT/EP2017/067581 WO2018011283A1 (en) | 2016-07-13 | 2017-07-12 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809879WA true SG11201809879WA (en) | 2018-12-28 |
Family
ID=56413654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809879WA SG11201809879WA (en) | 2016-07-13 | 2017-07-12 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11117954B2 (en) |
| EP (2) | EP4342911A1 (en) |
| JP (2) | JP7252888B2 (en) |
| KR (1) | KR102595764B1 (en) |
| CN (2) | CN109563157B (en) |
| BR (1) | BR112018074456A2 (en) |
| CA (1) | CA3024374A1 (en) |
| CL (2) | CL2019000067A1 (en) |
| CO (1) | CO2019001111A2 (en) |
| CR (1) | CR20190066A (en) |
| DK (1) | DK3484915T3 (en) |
| DO (2) | DOP2019000006A (en) |
| EA (1) | EA201990243A1 (en) |
| EC (1) | ECSP19009170A (en) |
| ES (1) | ES2959883T3 (en) |
| FI (1) | FI3484915T3 (en) |
| HR (1) | HRP20231196T1 (en) |
| HU (1) | HUE063272T2 (en) |
| IL (1) | IL262710B2 (en) |
| LT (1) | LT3484915T (en) |
| MX (1) | MX2019000526A (en) |
| MY (1) | MY190553A (en) |
| PE (1) | PE20190398A1 (en) |
| PH (1) | PH12018502348A1 (en) |
| PL (1) | PL3484915T3 (en) |
| SG (1) | SG11201809879WA (en) |
| SI (1) | SI3484915T1 (en) |
| UA (1) | UA126381C2 (en) |
| WO (2) | WO2018010789A1 (en) |
| ZA (1) | ZA201807467B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6998935B2 (en) | 2016-07-13 | 2022-01-18 | エボニック オペレーションズ ゲーエムベーハー | How to Separate Lipids from Dissolved Lipid-Containing Biomass |
| CU20190036A7 (en) | 2016-10-13 | 2019-11-04 | Massachusetts Inst Technology | ANTIBODIES THAT BIND THE ZIKA VIRUS ENVELOPE PROTEIN |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof |
| EP3527664A1 (en) | 2018-02-15 | 2019-08-21 | Evonik Degussa GmbH | Method of isolating lipids from a lipids containing biomass |
| JP2019152666A (en) * | 2018-03-02 | 2019-09-12 | 富士レビオ株式会社 | Method and kit for detecting zika virus |
| US11884718B2 (en) | 2018-04-24 | 2024-01-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination |
| US11976253B2 (en) | 2018-05-15 | 2024-05-07 | Evonik Operations Gmbh | Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion |
| CA3101855C (en) | 2018-05-15 | 2023-06-20 | Evonik Operations Gmbh | Method of isolating lipids from a lipids containing biomass with aid of hydrophobic silica |
| WO2020061159A1 (en) * | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
| WO2020078568A1 (en) | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
| BR112021008217A2 (en) * | 2018-10-31 | 2021-08-17 | Icahn School Of Medicine At Mount Sinai | human antibodies that target zika virus ns1, polypeptides ns1 and their uses |
| JP7463366B2 (en) | 2018-11-20 | 2024-04-08 | タケダ ワクチン，インコーポレイテッド | Novel anti-Zika virus antibodies and uses thereof |
| WO2020245663A1 (en) * | 2019-06-01 | 2020-12-10 | Institut Pasteur | Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection |
| BR112022009574A2 (en) * | 2019-11-19 | 2022-08-02 | Univ Vanderbilt | HUMAN ANTIBODIES THAT NEUTRALIZE THE ZIKA VIRUS AND METHODS OF USE THEREOF |
| CN111100201B (en) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | Murine monoclonal antibody against envelope protein of Zika virus |
| CN111138534B (en) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | Mouse source monoclonal antibody of Zika virus envelope protein |
| JP7471555B2 (en) | 2020-02-20 | 2024-04-22 | 国立感染症研究所長 | Flavivirus cross-neutralizing antibodies and pharmaceutical compositions |
| US20230324404A1 (en) | 2020-05-20 | 2023-10-12 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| US20230204567A1 (en) | 2020-05-20 | 2023-06-29 | Takeda Vaccines, Inc. | Method for determining the potency of antigens |
| CN115697392A (en) * | 2020-06-28 | 2023-02-03 | 神州细胞工程有限公司 | Method for reducing virus ADE effect |
| WO2022212858A2 (en) * | 2021-04-01 | 2022-10-06 | A2 Biotherapeutics, Inc. | Polypeptides targeting hla-a*11 and methods of use thereof |
| CN112921124B (en) * | 2021-04-08 | 2021-09-28 | 广东创晟控股集团有限公司 | Kit for rapidly detecting viruses |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (en) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | Novel urokinase derivative, its preparation and thrombolytic agent containing the same |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| AU2003263853A1 (en) * | 2002-08-16 | 2004-03-03 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
| EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| JP5091476B2 (en) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Use of hydrophobic interaction chromatography or hinge region modification to generate homogeneous antibody solutions |
| US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
| BRPI0914092B1 (en) | 2008-10-22 | 2021-08-31 | Institute For Research In Biomedicine | METHOD OF PRODUCTION OF AN ANTIBODY FROM PLASMA CELLS, METHOD OF PRODUCTION OF A MONOCLONAL ANTIBODY FROM PLASMA CELLS AND METHOD OF PRODUCTION OF AN ANTIBODY OR AN ANTIBODY FRAGMENT |
| EP3689902B1 (en) * | 2013-03-15 | 2023-06-28 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| JP2019511221A (en) | 2016-03-11 | 2019-04-25 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Attenuated live Dika virus vaccine |
| WO2017181098A2 (en) * | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| TW201815821A (en) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | Anti-zika virus antibodies and methods of use |
| CN117946114A (en) | 2017-07-28 | 2024-04-30 | 武田药品工业株式会社 | TYK2 inhibitor and application thereof |
-
2016
- 2016-07-13 WO PCT/EP2016/066684 patent/WO2018010789A1/en active Application Filing
-
2017
- 2017-07-12 FI FIEP17742985.9T patent/FI3484915T3/en active
- 2017-07-12 CN CN201780042888.7A patent/CN109563157B/en active Active
- 2017-07-12 HR HRP20231196TT patent/HRP20231196T1/en unknown
- 2017-07-12 CR CR20190066A patent/CR20190066A/en unknown
- 2017-07-12 EA EA201990243A patent/EA201990243A1/en unknown
- 2017-07-12 ES ES17742985T patent/ES2959883T3/en active Active
- 2017-07-12 DK DK17742985.9T patent/DK3484915T3/en active
- 2017-07-12 SG SG11201809879WA patent/SG11201809879WA/en unknown
- 2017-07-12 BR BR112018074456-5A patent/BR112018074456A2/en unknown
- 2017-07-12 PE PE2019000034A patent/PE20190398A1/en unknown
- 2017-07-12 JP JP2019501482A patent/JP7252888B2/en active Active
- 2017-07-12 IL IL262710A patent/IL262710B2/en unknown
- 2017-07-12 UA UAA201901101A patent/UA126381C2/en unknown
- 2017-07-12 US US16/317,533 patent/US11117954B2/en active Active
- 2017-07-12 WO PCT/EP2017/067581 patent/WO2018011283A1/en unknown
- 2017-07-12 CA CA3024374A patent/CA3024374A1/en active Pending
- 2017-07-12 PL PL17742985.9T patent/PL3484915T3/en unknown
- 2017-07-12 EP EP23191207.2A patent/EP4342911A1/en active Pending
- 2017-07-12 SI SI201731420T patent/SI3484915T1/en unknown
- 2017-07-12 HU HUE17742985A patent/HUE063272T2/en unknown
- 2017-07-12 CN CN202211721078.3A patent/CN116199775A/en active Pending
- 2017-07-12 KR KR1020197004192A patent/KR102595764B1/en active IP Right Grant
- 2017-07-12 MX MX2019000526A patent/MX2019000526A/en unknown
- 2017-07-12 EP EP17742985.9A patent/EP3484915B1/en active Active
- 2017-07-12 MY MYPI2018704108A patent/MY190553A/en unknown
- 2017-07-12 LT LTEPPCT/EP2017/067581T patent/LT3484915T/en unknown
-
2018
- 2018-11-07 ZA ZA2018/07467A patent/ZA201807467B/en unknown
- 2018-11-07 PH PH12018502348A patent/PH12018502348A1/en unknown
-
2019
- 2019-01-08 DO DO2019000006A patent/DOP2019000006A/en unknown
- 2019-01-09 CL CL2019000067A patent/CL2019000067A1/en unknown
- 2019-02-05 CO CONC2019/0001111A patent/CO2019001111A2/en unknown
- 2019-02-07 EC ECSENADI20199170A patent/ECSP19009170A/en unknown
-
2021
- 2021-02-10 DO DO2021000026A patent/DOP2021000026A/en unknown
- 2021-06-01 US US17/335,792 patent/US11912757B2/en active Active
- 2021-06-01 US US17/335,799 patent/US20210363227A1/en active Pending
- 2021-11-12 CL CL2021002994A patent/CL2021002994A1/en unknown
-
2023
- 2023-02-10 JP JP2023019144A patent/JP2023062036A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201408330XA (en) | Compositions and methods related to prevention and treatment of rabies infection | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells |